Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

Prompt recognition of autoimmune disease symptoms can help patients with chronic lymphocytic leukemia receive proper rheumatologic care. Immune dysregulation associated with chronic lymphocytic ...

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia? Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with ...

Chronic lymphocytic leukemia (CLL) cell–derived exosomes demonstrated the ability to alter healthy donor cell function and suppress normal blood cell formation. These particles affected monocytes, ...

Nanopore sequencing offers comparable accuracy to short-read NGS for IGH clonotyping in CLL, with advantages in cost and laboratory footprint. The study confirms reliable somatic hypermutation status ...

The treatment patterns and adverse reactions of bevacizumab in the Chinese population in the real world.

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a ...

The FDA has granted fast track designation to UB-VV111 for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) following 2 or more prior lines of therapy and relapsed/refractory chronic ...